Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.

Zhan M, Xu T, Wu F, Tang Y.

J Evid Based Med. 2012 Aug;5(3):154-65. doi: 10.1111/j.1756-5391.2012.01189.x. Review.

PMID:
23672222
2.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
4.

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.

Curr Med Res Opin. 2009 Mar;25(3):569-83. doi: 10.1185/03007990802705679 .

PMID:
19232032
5.

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D.

Diabetes Obes Metab. 2008 Jul;10(7):545-55. doi: 10.1111/j.1463-1326.2008.00914.x. Epub 2008 Jun 1.

PMID:
18518892
6.

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group.

Diabetes Care. 2006 Dec;29(12):2632-7.

PMID:
17130196
7.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.

PMID:
17130197
8.
9.

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Gerrald KR, Van Scoyoc E, Wines RC, Runge T, Jonas DE.

Diabetes Obes Metab. 2012 Jun;14(6):481-92. doi: 10.1111/j.1463-1326.2011.01540.x. Epub 2011 Dec 27. Review.

PMID:
22098472
10.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713.

PMID:
17485570
11.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
12.
13.

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP.

Diabetes Res Clin Pract. 2008 Feb;79(2):291-8. Epub 2007 Oct 22.

PMID:
17933414
14.

Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

Lu J, Zang J, Li H.

PLoS One. 2013 Oct 25;8(10):e76713. doi: 10.1371/journal.pone.0076713. eCollection 2013.

15.

Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.

Du Q, Wu B, Wang YJ, Yang S, Zhao YY, Liang YY.

Curr Med Res Opin. 2013 Nov;29(11):1487-94. doi: 10.1185/03007995.2013.833090. Epub 2013 Sep 5.

PMID:
23927568
16.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
17.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
18.

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . Review.

PMID:
18182122
19.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group.

Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14.

PMID:
18201203
20.

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x.

PMID:
21535346

Supplemental Content

Support Center